The German government-funded Institute for Quality and Efficiency in Health Care (“IQWiG”), tasked with policing the quality and efficiency of medical processes and products, has stated that Eylea (aflibercept) from Bayer AG (Xetra: BAYN) has “no additional benefit” over Lucentis (ranibizumab; Genentech/Roche). In short, the statement appears to arise from a failure by the manufacturer to include in its dossier usable data for the comparison with ranibizumab. The drug, developed by Regeneron Pharmaceuticals Inc., (REGN; Tarrytown, New York), is exclusively marketed by Bayer outside the US.
Germany’s Health Care agency (IQWiG) questions claims of additional benefits from Bayer’s Eylea (aflibercept)
- by swdadmin